Today, on 29 May, the JSC Grindeks submitted the non-audited consolidated financial statements for the first quarter of 2015 to “Nasdaq Riga”. Non-audited financial results indicate that the Group’s turnover amounted to 22.4 million euros and has increased by 3.6 million euros or 19.1% in comparison to the first quarter of 2014. While the Group’s net profit, attributable to shareholders of the parent company, was 1.4 million euros in the first quarter of 2015 and has increased by 0.9 million euros or 183% in comparison to the first quarter of 2014. Gross profit margin in the first quarter of 2015 was 52.1% while net profit margin was 6.5%. In the first quarter of 2015 the Group’s production was exported to 44 countries worldwide, a total of 20.5 million euros which is 2.7 million euros or 15.4% more than in the first quarter of 2014.
Sales volume of the final dosage forms of Grindeks in the first quarter of 2015 was 19.2 million euros and has increased by 3.1 million euros or 19.1% in comparison to the first quarter of 2014. The sales amount in Russia, other CIS countries and Georgia reached 12.3 million euros in the first quarter of 2015, which is by 1.1 million euros or 8% less than in the first quarter of 2014. Thanks to successful business diversification and the development of company’s activities in new markets, turnover of the final dosage forms in the Baltic States and other European countries amounted to 7 million euros, which is by 4.1 million euros or 148% more than in the first quarter of 2014. The sales volume in Latvia in the first quarter of this year accounted to 1.5 million euros and has increased by 0.6 million euros or 70% comparing with the first quarter of last year.
In the first quarter of 2015, sales of the active pharmaceutical ingredients reached 3.1 million euros, which is by 0.5 million euros or 17.8% more than in the first quarter of 2014. Main markets of Grindeks active pharmaceutical ingredients are the EU countries, USA and Japan. The most required active pharmaceutical ingredients of Grindeks in the first quarter of 2015 were Oxytocin, 6-thioguanine, Pimobendan and Ursodeoxycholic acid.
The Chairman of the Board Mr. Juris Bundulis: “By using company’s accumulated knowledge and experience in 60 countries worldwide, Grindeks successfully supplements its product portfolio and activities in new markets. This year’s first quarterly results affirm that currently implemented business diversification and restructuring are bringing positive results. The further company’s development will depend on two relevant factors – fast entrance into new markets and recovery of the economic situation in the CIS countries”.
